Propanc Biopharma, Inc. (PPCB) Peer Comparison

$1.01

$-0.01 (-0.98%)

As on 04-Sep-2026 16:16EDT

Market cap

$3 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

0

P/B Ratio

0.5

Div. Yield

0 %

Edit

	Propanc Biopharma, Inc. (PPCB)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Market cap ($ Mln)	3	16,765	16,261	13,492	12,332
Revenue ($ Mln)	0	2,782	1,054	2,436	1,284
Net Profit ($ Mln)	-18.36	491.50	755.85	860.62	-325.10
Net Margin (%)	-61,399.58	17.67	71.69	35.33	-25.32
RoE (%)	-151.81	110.09	--	42.98	-57.72
Price to Earnings	0.00	35.25	19.00	17.40	--
Price-To-Book	0.52	39.29	9.76	7.42	23.98

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Propanc Biopharma, Inc. (PPCB)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Operating Revenue	0.03	2,782.29	1,054.37	2,435.92	1,283.94
Cost of Revenue	0.02	1,982.07	103.47	85.67	109.42
Gross Profit	--	760.62	588.53	2,236.43	902.26
Operating Expenses	18.37	216.81	841.45	1,378.74	1,497.13
Operating Profit (EBIT)	-18.37	583.40	109.45	971.51	-322.62
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-18.36	598.92	101.11	1,035.47	-325.10
Provision for Tax	0.00	107.42	-654.74	174.84	0.00
Profit after Tax (Net Income)	-18.36	491.50	755.85	860.62	-325.10
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Propanc Biopharma, Inc. (PPCB)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Shareholder's Funds	9.83	433.86	1,435.90	1,843.76	523.72
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	1.03	187.89	384.48	288.55	346.72
Current Liabilities	3.48	1,435.43	464.70	361.93	374.20
Total Liabilities	19.63	1,975.47	1,302.02	2,844.42	1,259.59

Assets ($ Mln)

	Propanc Biopharma, Inc. (PPCB)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Non-Current Assets	6.11	1,006.90	895.24	1,243.41	45.47
Current Assets	8.22	1,050.29	1,389.84	1,250.82	1,199.18
Total Assets	19.63	1,975.47	1,302.02	2,844.42	1,259.59
Total Debt*	1.57	120.10	449.89	165.93	347.75
Net Current Assets	4.75	-385.14	0.00	888.90	824.98

Cashflow ($ Mln)

	Propanc Biopharma, Inc. (PPCB)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Cash From Operating Activities	-0.41	713.22	51.77	884.27	-189.55
Cash Flow from Investing Activities	--	-31.14	-8.15	350.44	32.32
Cash from Financing Activities	0.49	-860.39	34.89	-969.59	255.98
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Propanc Biopharma, Inc. (PPCB)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
ROCE (%)	-920.51	53.56	-30.01	32.82	-31.49
ROE (%)	-151.81	110.09	163.18	42.98	-57.72
ROA (%)	-82.19	15.64	26.53	29.32	-22.97
EBIT Margin (%)	-59,201.15	21.13	5.73	31.04	-18.97
Net Margin (%)	-61,399.58	17.67	71.69	35.33	-25.32
Cash Profit Margin (%)	-2.85	0.00	0.00	0.00	0.00

Growth Ratios

	Propanc Biopharma, Inc. (PPCB)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Revenue Growth (%)	--	24.67	114.85	9.23	149.04
EBIT Growth (%)	67.70	18.70	136.39	-3.99	9.16
Net Profit Growth (%)	66.74	17.50	378.76	42.89	-15.32
EPS Growth (%)	89.18	26.84	353.27	50.42	-0.64
Book Value Growth (%)	161.95	164.02	816.12	-0.70	-42.66

Valuation Ratios

	Propanc Biopharma, Inc. (PPCB)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Price / Earnings	-0.82	36.06	-59.76	15.79	-45.32
Price / Book Value	3.47	35.44	-80.42	5.72	21.68
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-0.86	28.08	-121.54	12.44	-47.02
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Propanc Biopharma, Inc. (PPCB)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Debt to Equity	0.00	0.00	0.00	0.00	0.65
Short term debt to equity ratio	0.06	0.00	0.05	0.00	0.00
Current Ratio	2.37	0.73	2.99	3.46	3.20
Quick Ratio	2.37	0.73	2.32	3.38	2.94
Interest Coverage	-26.93	--	1.62	--	-19.80

Operating Efficiency Ratios

	Propanc Biopharma, Inc. (PPCB)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Debtors to sales (%)	36.97	15.88	21.25	13.74	14.98
Asset Turnover	0.00	0.89	0.37	0.83	0.91
Receivable days	--	50.42	85.52	43.48	35.88
Inventory Days	--	--	1,056.70	96.17	354.23
Payable days	--	6.26	331.01	147.97	300.79
Cash Conversion Cycle	--	--	811.21	-8.32	89.33

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly